The latest developments
Calithera's $480M+ tie-up with Incyte re arginase bid beats hard on combo drum
After one analyst earlier this month referred to Calithera Biosciences Inc...
Lightstone Ventures Adds Susan Molineaux as Scientific Advisor
Calithera Biosciences Announces FDA Acceptance of Investigational New Drug Application for CB-1158, a Novel Arginase Inhibitor Targeting an Immune Metabolic Checkpoint
CALA: We Have Initiated Coverage With an Outperform Rating: CB-839: Novel Cancer Therapy Targeting Cancer Cell Metabolism
Calithera files to raise up to $80 million in IPO
Is Calithera the next biotech IPO hopeful?
Series D to Boost Calitera Cancer Compound into Phase I
Calithera Biosciences Secures $35 Million in Series D Financing
© 2013 LIGHTSTONE VENTURES